Get the app
US › Healthcare

Keros Therapeutics Inc (KROS)

US · Healthcare · Biotechnology

$10.66-3.96%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$18.2M
Revenue YoY
0.0%
Net profit
$-28.7M
EPS
$-1.45
EPS estimate
$-1.25
Net margin
-158.0%

EPS came in at -1.45 against a street estimate of -1.25 — a miss of 16.0%.

Key statistics

Market cap
$222.7M
Forward P/E
48.8
P/B
0.88
Book value
$13.23
EPS (TTM)
$-3.22
52-week high
$22.55
52-week low
$9.69
50-day MA
$11.10
200-day MA
$12.64
Beta
1.12

Analyst view

Analysts rate Keros Therapeutics Inc a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $19.83.

Shareholding

Insiders
3.96%
Institutions
95.24%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC14.23%
BlackRock Inc14.09%
AQR Capital Management LLC4.88%
Vanguard Capital Management, LLC4.20%
Orbimed Advisors LLC3.83%
Federated Hermes Inc3.53%
Vanguard Portfolio Management, LLC3.29%
Mackenzie Investments3.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Keros Therapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.